Survey for Those Who See Patients with Alzheimer’s or Related Dementias

Do you practice in the United States? *

Yes

No

What is your highest attained degree? Other, Please specify

What is your specialty? Other, Please specify

How many years have you been in practice?

Which best describes your current practice setting? *

Which best describes your current practice setting? Other, Please specify

Do you initiate a conversation about cognitive problems with your patients as part of a routine exam? *

Yes

No

I don’t initiate the conversation but will address cognitive complaints or issues my patients may have

How confident are you in your ability to accurately diagnose Alzheimer’s disease and differentiate it from other forms of dementia? *

Do you conduct any regular screening procedures for Alzheimer’s disease? *

Yes

No

What percent of your patients actually have a formal diagnosis of Alzheimer’s disease? *

Do you believe that currently available therapies to manage Alzheimer’s disease offer some disease-modifying properties in addition to offering symptomatic benefits? *

Yes

No

Do you believe that blocking the toxic form of amyloid that produces plaques in the brain is still a viable approach to developing disease-modifying treatments for Alzheimer’s? *

Yes

No

Please rate your familiarity with the following drug classes that are currently in clinical development for aMCI, MCI, and/or Alzheimer’s disease: *

	Not at all familiar	Somewhat familiar	Very familiar	Extremely familiar
BACE inhibitors (Beta-site APP-cleaving Enzyme)	BACE inhibitors (Beta-site APP-cleaving Enzyme) - Not at all familiar	BACE inhibitors (Beta-site APP-cleaving Enzyme) - Somewhat familiar	BACE inhibitors (Beta-site APP-cleaving Enzyme) - Very familiar	BACE inhibitors (Beta-site APP-cleaving Enzyme) - Extremely familiar
RAGE Antagonist (Receptor for advanced glycation endproducts)	RAGE Antagonist (Receptor for advanced glycation endproducts) - Not at all familiar	RAGE Antagonist (Receptor for advanced glycation endproducts) - Somewhat familiar	RAGE Antagonist (Receptor for advanced glycation endproducts) - Very familiar	RAGE Antagonist (Receptor for advanced glycation endproducts) - Extremely familiar
5-HT6 receptor antagonists	5-HT6 receptor antagonists - Not at all familiar	5-HT6 receptor antagonists - Somewhat familiar	5-HT6 receptor antagonists - Very familiar	5-HT6 receptor antagonists - Extremely familiar
Tau aggregation inhibitors	Tau aggregation inhibitors - Not at all familiar	Tau aggregation inhibitors - Somewhat familiar	Tau aggregation inhibitors - Very familiar	Tau aggregation inhibitors - Extremely familiar
Tau vaccine	Tau vaccine - Not at all familiar	Tau vaccine - Somewhat familiar	Tau vaccine - Very familiar	Tau vaccine - Extremely familiar
Anti Amyloid Beta monoclonal antibodies	Anti Amyloid Beta monoclonal antibodies - Not at all familiar	Anti Amyloid Beta monoclonal antibodies - Somewhat familiar	Anti Amyloid Beta monoclonal antibodies - Very familiar	Anti Amyloid Beta monoclonal antibodies - Extremely familiar
Microglial modulators	Microglial modulators - Not at all familiar	Microglial modulators - Somewhat familiar	Microglial modulators - Very familiar	Microglial modulators - Extremely familiar
Low dose antiepileptic	Low dose antiepileptic - Not at all familiar	Low dose antiepileptic - Somewhat familiar	Low dose antiepileptic - Very familiar	Low dose antiepileptic - Extremely familiar
Muscarinic (M) agonists	Muscarinic (M) agonists - Not at all familiar	Muscarinic (M) agonists - Somewhat familiar	Muscarinic (M) agonists - Very familiar	Muscarinic (M) agonists - Extremely familiar

Which of the following companies do you associate most closely with research in the area of BACE inhibition for Alzheimer’s disease? Select all that apply. *

If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following:

First Name:

Last Name:

Email:

You are here

Survey for Those Who See Patients with Alzheimer’s or Related Dementias